Prasco Laboratories Enters into Agreement with Sanofi-Aventis (France) to Market the Authorized Generic Versions of Ambien(R) (Zolpidem Tartrate) CIV

CINCINNATI--(BUSINESS WIRE)--Prasco announced today it has signed a distribution and supply agreement with sanofi-aventis U.S. to launch authorized generic versions of Ambien® in the United States. The authorized generic Zolpidem Tartrate will be marketed in 5 mg and 10 mg strengths.
MORE ON THIS TOPIC